BREAKING: A flurry of FDA news has hit our desks this past week across several subspecialties. Learn the latest on each development: Ryzumvi: hubs.li/Q04BCyyB0 TED: hubs.li/Q04BCyBp0 Brytly: hubs.li/Q04BCyCj0

The Sept/Oct issue of Optometry Times® is live! 👀 🔬 Oculomics in optometry 👁️ Safe contact lens habits 🐟 Omega-3s & dry eye 💡 Light-based tech for MGD 👇 Check Out the Articles From the Sept/Oct Issue on Optometry Times: hubs.li/Q04B7tPB0  #Optometry #DryEye

Highlights from AAOpt 2026! We had a wonderful time at this year's conference. To read our coverage, visit our website here: optometrytimes.com/conferenc…

That's a wrap on AAOpt Day 3! Keep an eye on our website for the full interviews: optometrytimes.com/conferenc…

Day 2 is in the books! Stay tuned for our full interviews, and keep up with our coverage here: hubs.ly/Q04y_XHX0

Day 1 of AAOpt 2026 completed ✅ Thank you to everyone who shared their insights and expertise on the exciting new developments in optometry. Stay tuned for the full interviews, and follow our AAOpt 2026 coverage here: hubs.li/Q04ySbSt0

David Webley, BSc (Hons), MCOptom, FBCLA, discussed the latest data on children's viewing and gaze behavior with SightGlass Vision's DOT spectacle lenses. Watch the full interview here: hubs.li/Q04yQFp_0

Welcome to Anaheim! We're so excited to be at this year's American Academy of Optometry Conference. For the latest insights from presenters and attendees, read our conference coverage here: hubs.ly/Q04yNQ790

👁️ This week in optometry: Major developments in the field of myopia take the spotlight. Experts also weight in on AI in practice, oculomics, and next week's AAOpt 2026 meeting. Find out what to look forward to in our recap: hubs.li/Q04ynfHK0

Leslie Scher, OD, shared her advice for performing vision screenings for athletes with intellectual disabilities at the Special Olympics. Watch the full interview here: hubs.li/Q04yh99J0 #optometry #pediatrics #specialolympics #eyecare

BREAKING: The FDA will convene an Advisory Committee on October 30, 2026, to review the SYD-101 (atropine 0.01%; Sydnexis) application for pediatric progressive myopia (PPM), according to a new announcement from Sydnexis. Read more here: hubs.li/Q04ygrw_0

As Myopia Awareness Month comes to a close, Dr Monica Jong, Head of Medical Affairs North America at EssilorLuxottica, spoke on how the Stellest lenses will contribute to the improvement of myopia preventative care. Watch the full interview: hubs.li/Q04yd1w00

👁️This week in Optometry: A recent AMA resolution backs classifying myopia as a disease, aiming to expand insurance coverage for pediatric myopia control treatments. Experts also weigh in on AI integration, comanagement, and CVI. Read our full coverage: hubs.li/Q04xW3xV0

👁️ This week on Optometry Times, leaders in the field share their perspectives on GLP-1s, neural roots of CVI, and integrating AI technology in practice. To learn more about the latest eye care developments, check out our recap: hubs.li/Q04xhX_W0

👁️ In this week's clinical roundup from Optometry Times, expert clinical insights on CVI and light-based therapy take the spotlight. For the latest research updates and chairside advice, check out the full recap: hubs.ly/Q04wMrkh0

Mile Brujic, OD, FAAO, of Premier Vision Group shares two easy strategies for reducing digital eye strain as students head back to school, when many kids spend hours on tablets for schoolwork. Learn more about pediatric patient care on our website: hubs.li/Q04rqdkW0

👁️ In this week's recap from Optometry Times, new FDA expansions and approvals in glaucoma and dry eye take the spotlight. For the latest research developments and practical advice from leaders in the field, check out the full recap: hubs.li/Q04vMHkw0

We spoke to optometrists around the country about how they prepare for new, and returning, patients during the back to school season. Watch the recap and full interviews here: hubs.li/Q04vLcRB0

BREAKING: The FDA has accepted for review the new drug application (NDA) for Kowa Pharmaceuticals America’s K-911 (bimatoprost grenod; also known as NCX 470). Read more: hubs.li/Q04vzTDT0

Carolyn Majcher, OD, FAAO, discussed her prediction for how physicians will implement changes in nAMD treatment following FDA approval of bevacizumab-vikg (Lytenava). For the full video, visit hubs.li/Q04vcsp-0